From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a poor prognosis despite advances in treatment strategies. Standard treatment regimens induce remissions in many patients, but relapse occurs in approximately half, highlightin…